articleTop 1% cited

Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration

Ophthalmology · 2016 · Vol. 123(8) · pp. 1751–1761

Maureen G. Maguire✉(University of Pennsylvania)Daniel Martín(Cleveland Eye Clinic)Gui‐Shuang Ying(University of Pennsylvania)Glenn J. Jaffe(Duke University)Ebenezer Daniel(University of Pennsylvania)Juan E. Grunwald(University of Pennsylvania)Cynthia A. Toth(Duke University)Frederick L. Ferris(National Institutes of Health)Stuart L. Fine(University of Colorado Denver)

View via DOI Publisher page

Retinal Diseases and Treatments Retinal Imaging and Analysis Ocular Diseases and Behçet’s SyndromeMedicineMacular degenerationRanibizumabFluorescein angiographyVisual acuityOphthalmologyPro re nataBevacizumabChoroidal neovascularizationClinical trial

MeSH terms

BevacizumabRanibizumabAgedAged, 80 and overFemaleFluorescein AngiographyFollow-Up StudiesHumansMaleProspective StudiesRetinaVisual AcuityCohort StudiesTreatment OutcomeAngiogenesis Inhibitors

Citations

690

FWCI

64.18

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

References

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2